Scalable brain stimulation for clinical routine
Sooma tDCS™ is the first EU MDR-approved tDCS system — a safe, drug-free, non-invasive treatment for depression and chronic pain. Administered in-clinic or at home under remote supervision as alternative or in-combination with medication.
Depression treatment
The next evolution in treating depression is here. Sooma tDCS is a revolutionary noninvasive brain stimulation treatment that effectively relieves patient symptoms – as well as patient queues at the clinic.
Pain management
Chronic pain conditions typically involve a complex array of symptoms – to which Sooma tDCS brain stimulation is the simple, innovative, and drug-free solution. Help the brain drive the pain away.
Trusted by clinicians
Dr. Ulrike Vogelmann, Managing Senior Physician at the Department of Psychiatry and Psychotherapy at the Technical University of Munich, shares her experience with Sooma tDCS and the difference it has made for her patients.
What is Sooma tDCS™?
Sooma tDCS combines pioneering brain stimulation technology with remote management in one easy-to-use system for effective data-driven clinical care.
Delivered through a portable device, the treatment utilizes transcranial direct current stimulation (tDCS) to relieve symptoms. It’s noninvasive, drug-free, and proven effective.
Improvement of symptoms typically within 3 weeks
without systemic side effects
Safe, high-quality, and scalable care
through a cost-effective solution
Increased patient flows and shorter queues
via optimized resources and remote care
Easy adoption and onboarding
with simple treatment protocols and user training
Results by the numbers
30,000+
patients treated in more than 35 countries
55%
of patients experienced relief in as little as 3 weeks in large peer-reviewed study*
300+
hospitals and clinics providing Sooma tDCS treatment
500,000+
treatment sessions administered worldwide for both research and patient care
* Lõokene M, Markov N, Nikander M, Neuvonen T, Dilkov D. Reduction of symptoms in patients with major depressive disorder after transcranial direct current stimulation treatment: A real-world study. Journal of Affective Disorders Reports, Volume 8, 2022. https://doi.org/10.1016/j.jadr.2022.100347.
What do clinicians and patients think?
Sooma tDCS has helped thousands of patients find relief and a better quality of life. But don’t just take our word for it – read what clinicians and patients have to say about the benefits of our noninvasive brain stimulation treatment.
Research with Sooma tDCS™
Sooma tDCS is a flexible platform for in-clinic and at-home studies for both tDCS and tACS. Wide parameter range combined with validated double-blind design makes it an ideal candidate for interventional studies
Sooma currently collaborates with researchers globally to improve patient care across multiple indications. Our fully remote FDA trial is currently recruiting patients with major depressive disorder in the US.
Meet us at following events
- 23-26.9.2026: World Congress of Psychiatry – Sweden
- 15-17.10.2026: European Conference of Brain Stimulation – Italy
- 28-30.10.2026: 3rd ESBS NIBS Certification Course – Germany
- 4-5.11.2026: Turun Lääketiedepäivät – Finland
- 2-6.12.2026: Congrès Français de Psychiatrie – France
